Review of cryptogenic fibrosing alveolitis, including current treatment guidelines

Postgraduate Medical Journal

Volumn 76, Issue 900, 2000, Pages 618-624

  Bourke, S C ^a   Clague, H ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; PENICILLAMINE; PREDNISOLONE;

ARTHRALGIA; CLINICAL TRIAL; CLUBBING FINGERS; COR PULMONALE; COUGHING; DISEASE ASSOCIATION; DOSE RESPONSE; DUST EXPOSURE; DYSPNEA; FIBROSING ALVEOLITIS; HEMATOLOGIC DISEASE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MORTALITY; OCCUPATIONAL EXPOSURE; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; SURVIVAL; UNITED KINGDOM;

AGED; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; DRUG THERAPY, COMBINATION; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PREDNISOLONE; PULMONARY FIBROSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033786980     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.76.900.618     Document Type: Review

References (51)

1. The diagnosis, assessment, and treatment of diffuse parenchymal lung disease in adults
2. The epidemiology of interstitial lung disease
3. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust
4. British Thoracic Society study of cryptogenic fibrosing alveolitis: Current presentation and initial management
5. Cryptogenic fibrosing alveolitis: Clinical features and their influence on survival
6. The prognosis of cryptogenic fibrosing alveolitis
7. Prognosis of cryptogenic fibrosing alveolitis
8. Rising mortality from cryptogenic fibrosing alveolitis
9. Mortality rates from cryptogenic fibrosing alveolitis in seven countries
10. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis
11. Cigarette smoking as a risk factor for idiopathic pulmonary fibrosis
12. Idiopathic pulmonary fibrosis: Epidemiological approaches to occupational exposure
13. Occupational and environmental risk factors for idiopathic pulmonary fibrosis
14. Hypothesis: Exposure to solvents may cause fibrosing alveolitis
15. Exposure to commonly prescribed drugs and the aetiology of cryptogenic fibrosing alveolitis: A case-control study
16. Viruses and idiopathic pulmonary fibrosis
17. Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polynmerase chain reaction
18. Aerosolised ribivarin in patients with advanced cryptogenic fibrosing alveolitis: A pilot study
19. Cryptogenic fibrosing alveolitis and Epstein-Barr virus: An association
20. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis
21. EBV PCR (Raji I) in idiopathic pulmonary fibrosis and sarcoidosis
22. Cryptogenic fibrosing alveolitis does not appear to be associated with Epstein-Barr virus infection
23. Familial idiopathic pulmonary fibrosis: Evidence of lung inflammation in unaffected family members
24. Natural history and treated course of usual and desquamative interstitial pneumonia
25. Non-specific interstitial pneumonia/fibrosis
26. Acute diffuse interstitial fibrosis
27. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis
28. Idiopathic pulmonary fibrosis: Clinical, histological, radiographic, physiologic, scintigraphic, cytological and biochemical aspects
29. Clinical significance of pulmonary function tests: Pulmonary function testing in interstitial pulmonary disease: What does it tell us?
30. Correlation of structure and function in idiopathic pulmonary fibrosis
31. Cryptogenic fibrosing alveolitis with normal lung evolumes
32. Changes in pulmonary function test results after one year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis
33. Idiopathic pulmonary fibrosis. Predicting response to therapy and survival
34. 99mTc-DPTA predicts the clinical course of fibrosing alveolitis
35. Normal chest roentgenograms in chronic diffuse infiltrative lung disease
36. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by lung biopsy. A prospective study
37. Fibrosing alveolitis: CT-pathologic correlation
38. High resolution computed tomography as a predictor of lung histology in systemic sclerosis
39. Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation
40. Importance of ground glass attenuation in chronic diffuse infiltrative lung disease: Pathologic-CT correlation
41. Accuracy of the typical computed tomographic appearances of fibrosing alveolitis
42. Chronic diffuse infiltrative lung disease: Comparison of diagnostic accuracy of CT and chest radiography
43. Serial CT in fibrosing alveolitis: Prognostic significance of the initial pattern
44. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT
45. State of the art. CT evaluation of fibrosing alveolitis - Applications and insights
46. The value of serial bronchoalveolar lavages in assessing the clinical response of patients with cryptogenic fibrosing alveolitis
47. Cryptogenic fibrosing alveolitis: Response to corticosteroid treatment and its effect on survival
48. Azathioprine combined with prednisolone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomised placebo-controlled clinical trial
49. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis
50. Colchicine versus prednisolone in the treatment of idiopathic pulmonary fibrosis
51. State of the art. Lung transplantation